Crescent Biopharma
CBIO
36 hedge funds and large institutions have $3M invested in Crescent Biopharma in 2024 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 4 increasing their positions, 12 reducing their positions, and 10 closing their positions.
10% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 10
3% more funds holding
Funds holding: 35 → 36 (+1)
12.06% less ownership
Funds ownership: 39.65% → 27.59% (-12%)
67% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 12
82% less capital inflows, than outflows
Capital inflows: $520K | Capital outflows: $2.84M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Advisers
New York
|
+$29.4K |
| 2 |
HWA
HCR Wealth Advisors
Los Angeles,
California
|
+$21K |
| 3 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$17.6K |
| 4 |
Two Sigma Investments
New York
|
+$9.36K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$7.13K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AG
Artal Group
Luxembourg
|
-$2.42M |
| 2 |
Goldman Sachs
New York
|
-$227K |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
-$37.2K |
| 4 |
Millennium Management
New York
|
-$35.1K |
| 5 |
SIG
Sargent Investment Group
Bethesda,
Maryland
|
-$28.2K |
CBIO Hedge Fund Activity: Q3 2024 in Review
36 of the 6,983 institutional investors tracked by Wall St. Rank reported a position in Crescent Biopharma (CBIO) for Q3 2024, worth a combined $3M — down 58% from $7.2M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new CBIO positions and 10 closed out — a net gain of 1 holder — while 4 added to existing stakes and 12 trimmed.
The largest buyer was Two Sigma Advisers, adding an estimated $29.4K. The largest seller was Artal Group, exiting entirely with an estimated $2.42M sold.
- 36 institutional investors held Crescent Biopharma (CBIO) as of Q3 2024, up from 35 in Q2 2024.
- Funds reported $3M of Crescent Biopharma stock for Q3 2024, down 58% quarter-over-quarter.
- 11 funds opened new Crescent Biopharma positions in Q3 2024 and 10 closed out, a net change of +1 holder.
- The largest Crescent Biopharma buyer in Q3 2024 was Two Sigma Advisers, an estimated $29.4K added.
- The largest Crescent Biopharma seller in Q3 2024 was Artal Group, an estimated $2.42M sold.
Based on aggregated 13F filings for Q3 2024.